Waters XenoTech has begun offering new metabolite profiling services. This has been possible with the Synapt High Definition Mass Spectrometry (HDMS) System.

The Defense Research and Development Organisation (DRDO) has succeeded in identifying two species of herbs carrying elements for a potential drug for malaria and is hopeful of bringing it to the market within two years as an alternative to existing drugs like chloroquine.

Sciele Pharma, Inc., a Shionogi company, and Plethora Solutions Holdings PLC announced the completion of patient recruitment of the PSD502 registration programme for the treatment of premature ejaculation (PE).

Seattle Genetics, Inc, announced that it has initiated a pivotal trial of SGN-35 for patients with relapsed or refractory Hodgkin lymphoma. The trial is being conducted under a Special Protocol Assessment (SPA), which is an agreement between the US Food and Drug Administration (FDA) and Seattle Genetics regarding the trial design necessary to support an efficacy claim in a New Drug Application (NDA). SGN-35 is an antibody-drug conjugate (ADC) that utilizes Seattle Genetics' proprietary technology to empower antibodies by linking them to potent cell-killing drugs.